NASDAQ$CODX
Co-Diagnostics Inc · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported financial results for the quarter ended September 30, 2024.
Co-Diagnostics announced their Q3 2024 financial results, highlighting progress in their pipeline development and ongoing dialogue with the FDA regarding their 510(k) application.
- Maintained active dialogue with the FDA throughout their substantive review of 510(k) application.
- Advanced all tests in pipeline towards completion, regulatory submission, and commercialization.
- Believe that COVID-19, tuberculosis, multiplex respiratory, and HPV multiplex tests on the Co-Dx PCR platform have the potential to increase access to state-of-the-art PCR diagnostics.
- Team working hard to make mission a reality and drive test developments forward.
Headline financials
Revenue & EPS history
Co-Diagnostics · Revenue · Quarterly
$641K
Revenue by segment
Co-Diagnostics · $146K total across 1 segment · Q1 2026
- Product$146K—100.0%
Forward guidance
Co-Diagnostics is making significant progress on tests and looks forward to providing regulatory and commercialization updates as they develop.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2024
-5.3%
Avg return
Earnings day
-3.9%
Avg return
5 days after
+0.6%
Avg return
30 days after
34%
12 / 35 earnings
Positive
+21.0%
Q1 2022
Best reaction
-32.3%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.6% | +24.4% | +169.2% | |
| Q3 2025 | -11.4% | -8.1% | -8.3% | |
| Q2 2025 | +11.7% | +6.4% | +28.7% | |
| Q1 2025 | -2.4% | -2.8% | -15.5% | |
| Q4 2024 | -18.3% | -8.7% | -10.7% | |
| Q3 2024 | -5.8% | -3.3% | -29.7% | |
| Q2 2024 | +4.7% | +9.3% | +25.2% | |
| Q1 2024 | -9.0% | -8.2% | +10.7% | |
| Q4 2023 | -9.3% | -6.8% | +1.7% | |
| Q3 2023 | -7.3% | +9.8% | -0.8% | |
| Q2 2023 | -10.8% | -6.9% | -5.4% | |
| Q1 2023 | +0.8% | +4.9% | -20.9% | |
| Q4 2022 | -14.8% | -34.4% | -46.4% | |
| Q3 2022 | +8.6% | +9.7% | -17.4% | |
| Q2 2022 | -32.3% | -37.9% | -50.6% | |
| Q1 2022 | +21.0% | +33.8% | +35.1% | |
| Q4 2021 | -8.3% | +4.0% | -24.4% | |
| Q3 2021 | +7.8% | +13.1% | -2.3% | |
| Q2 2021 | +11.0% | +15.6% | +10.8% | |
| Q1 2021 | +15.7% | +20.4% | +20.8% | |
| Q4 2020 | -21.8% | -31.1% | -27.8% | |
| Q3 2020 | -20.6% | -26.0% | -28.8% | |
| Q2 2020 | -16.8% | -21.2% | -29.9% | |
| Q1 2020 | -27.1% | -19.5% | -33.5% | |
| Q4 2019 | -16.7% | -10.4% | +35.2% | |
| Q3 2019 | -4.3% | -3.9% | +7.1% | |
| Q2 2019 | -11.1% | -8.1% | -13.5% | |
| Q1 2019 | -14.2% | -20.3% | -25.7% | |
| Q4 2018 | +5.6% | +0.0% | -8.2% | |
| Q3 2018 | +2.3% | -9.3% | -13.1% | |
| Q2 2018 | -1.4% | -4.5% | -10.8% | |
| Q1 2018 | -8.1% | -7.0% | +129.7% | |
| Q4 2017 | -5.9% | -11.3% | -14.9% | |
| Q3 2017 | -3.2% | -6.8% | -43.4% | |
| Q2 2017 | +3.2% | +9.4% | +29.0% | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro